密度 | 1.163?g/mL?at 25?°C |
---|---|
沸点 | 100?°C |
熔点 | 460?°C (dec.) |
分子式 | C8H7NaO3S |
分子量 | 206.194 |
精确质量 | 206.001358 |
PSA | 65.58000 |
LogP | 2.32500 |
外观性状 | powder |
折射率 | n20/D 1.395 |
储存条件 |
保持贮藏器密封 放入紧密的贮藏器内,储存在阴凉,干燥的地方 |
稳定性 |
如果遵照规格使用和储存则不会分解 避免接触氧化物 |
水溶解性 | water and lower glycols: soluble | SOLUBLE |
计算化学 |
1.疏水参数计算参考值(XlogP):1.4 2.氢键供体数量:1 3.氢键受体数量:3 4.可旋转化学键数量:2 5.互变异构体数量:无 6.拓扑分子极性表面积62.8 7.重原子数量:12 8.表面电荷:0 9.复杂度:242 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 |
1. 性状:淡黄色液体,无臭味 2. 密度(g/mL,25/4℃):0.801 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(oC):460 5. 沸点(oC,常压):未确定 6. 沸点(oC,5.2kPa):未确定 7. 折射率:未确定 8. 闪点(oC):未确定 9. 比旋光度(o):未确定 10. 自燃点或引燃温度(oC):未确定 11. 蒸气压(kpa,20oC):未确定 12. 饱和蒸气压(kPa,60oC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(oC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:易溶于水 |
聚苯乙烯磺酸钠毒性英文版
|
个人防护装备 |
Eyeshields;Gloves;half-mask respirator (US);multi-purpose combination respirator cartridge (US) |
---|---|
安全声明 (欧洲) |
24/25 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 2 |
RTECS号 | DB8550000 |
Surface functionality as a means to impact polymer nanoparticle size and structure. Langmuir 29(12) , 4092-5, (2013)
When polymeric nanoparticles (NPs) are formed by nanoprecipitation, which is a nucleation-growth process, the control over size requires changing the polymer concentration or solvent composition. Here…
|
|
A novel pulsed drug-delivery system: polyelectrolyte layer-by-layer coating of chitosan-alginate microgels. Int. J. Nanomedicine 8 , 877-87, (2013)
The aim of this report was to introduce a novel “core-membrane” microgel drug-delivery device for spontaneously pulsed release without any external trigger.The microgel core was prepared with alginate…
|
|
Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am. J. Med. 126(3) , 264.e9-24, (2013)
Sodium polystyrene sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia. However, its use has been associated with colonic …
|
|
MFCD00084449 |
sodium p-styrene sulfonate |
Styrene-4-sulfonic acid sodium salt |
4-STYRENESULFONIC ACID, SODIUM SALT |
4-Vinylbenzenesulfonic acid sodium salt |
sodium 4-ethenylbenzenesulfonate |
EINECS 220-266-3 |
Benzenesulfonic acid, 4-ethenyl-, sodium salt |
Benzenesulfonic acid, 4-ethenyl-, sodium salt (1:1) |
sodium 4-styrene sulfonate |
Sodium 4-vinylbenzenesulfonate |